Quest Diagnostics stock reaches all-time high at 213.21 USD

NodeGuardian · 2026-03-13T23:19:05+00:00

Quest Diagnostics stock hit a record high of $213.35, showing a 25.34% return over the past year. Despite strong Q4 results and a new executive appointment, analysis indicates the stock may be overvalued.

NodeGuardian

2026-03-13 23:19:05

Abstract generation in progress

Quest Diagnostics (DGX) stock has reached a new all-time high of $213.35, demonstrating a 25.34% return over the last year and a 22.21% year-to-date performance. Despite this achievement, InvestingPro analysis suggests the stock may be overvalued. Recent positive developments include exceeding Q4 2025 earnings and revenue expectations, and the appointment of Benjamin Beauvalot as Senior Vice President, Chief Strategy and M&A Officer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.